Suchergebnisse - Alexandra Pender

The efficacy of crizotinib in patients with -positive nonsmall cell lung cancer von Alexandra Pender, Sanjay Popat

Volltext

Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy von Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho

Volltext

Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing von Lauren Jones, Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho

Volltext

Effect of targeted therapy and immunotherapy on advanced nonsmall‐cell lung cancer outcomes in the real world von Aria Shokoohi, Zamzam Al‐Hashami, Sara Moore, Alexandra Pender, Selina K. Wong, Ying Wang, Bonnie Leung, Jonn Wu, Cheryl Ho

Volltext

Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults von Bonnie Leung, Aria Shokoohi, Zamzam Al-Hashami, Sara Moore, Alexandra Pender, Selina K. Wong, Ying Wang, Jonn Wu, Cheryl Ho

Volltext

Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach. von Alexandra Pender, Isaac Garcia-Murillas, Sareena Rana, Rosalind J Cutts, Gavin Kelly, Kerry Fenwick, Iwanka Kozarewa, David Gonzalez de Castro, Jaishree Bhosle, Mary O'Brien, Nicholas C Turner, Sanjay Popat, Julian Downward

Volltext